Chronic infections are difficult to treat with antibiotics but are caused primarily by drug-sensitive pathogens. Dormant persister cells that are tolerant to killing by antibiotics are responsible for this apparent paradox. Persisters are phenotypic variants of normal cells and pathways leading to dormancy are redundant, making it challenging to develop anti-persister compounds. Biofilms shield persisters from the immune system, suggesting that an antibiotic for treating a chronic infection should be able to eradicate the infection on its own. We reasoned that a compound capable of corrupting a target in dormant cells will kill persisters. The acyldepsipeptide antibiotic (ADEP4) has been shown to activate the ClpP protease, resulting in death of growing cells. Here we show that ADEP4-activated ClpP becomes a fairly nonspecific protease and kills persisters by degrading over 400 proteins, forcing cells to self-digest. Null mutants of clpP arise with high probability, but combining ADEP4 with rifampicin produced complete eradication of Staphylococcus aureus biofilms in vitro and in a mouse model of a chronic infection. Our findings indicate a general principle for killing dormant cells-activation and corruption of a target, rather than conventional inhibition. Eradication of a biofilm in an animal model by activating a protease suggests a realistic path towards developing therapies to treat chronic infections.
The current antibiotic crisis stems from two distinct phenomena, drug resistance and drug tolerance. Resistance mechanisms such as drug efflux or modification prevent antibiotics from binding to their targets 1 , allowing pathogens to grow. Antibiotic tolerance is the property of persister cells, phenotypic variants of regular bacteria 2 . Antibiotics kill by corrupting their targets, but these are inactive in dormant persisters, leading to tolerance 3, 4 . Persisters were discovered by Joseph Bigger in 1944, when he found that a small sub-population of Staphylococcus aureus survives treatment with penicillin 5 . We identified persisters as the main component responsible for drug tolerance of biofilms 6 . A multitude of chronic diseases is associated with biofilms: endocarditis, osteomyelitis, infections of catheters and indwelling devices, gingivitis and deep-seated infections of soft tissues 7, 8 . In Escherichia coli, which has served as a model organism for studying persisters, pathways leading to dormancy are highly redundant and largely depend on the action of toxin/antitoxin modules 3, 9 . Protein synthesis inhibition by the HipA toxin 10, 11 , a kinase 12 that phosphorylates glutamyl-transfer RNA synthetase GltX 11 , and by at least 10 different messenger RNA endonucleases such as RelE, MazF and YafQ 3,9,13,14 leads to dormancy. Damage of DNA induces the SOS response and expression of the TisB toxin 15 , which is an endogenous antimicrobial peptide 16 and causes persister formation by opening an ion channel 17 . This decreases the proton motive force and ATP levels, leading to target shutdown and a dormant, drug-tolerant state. The multiplicity of dormancy pathways precludes development of drugs that could prevent persister formation 18 . We reasoned that a compound capable of corrupting a target in dormant, energy-deprived cells will kill persisters. Acyldepsipeptide (ADEP) activates the ClpP protease, and it was reported to kill growing cells 19 . Normally, ClpP recognizes and eliminates misfolded proteins with the aid of ATP-dependent ClpX, C or A subunits 20 . ADEP binds to ClpP and keeps the catalytic chamber open, allowing entry to peptides and proteins 21, 22 . In the presence of ADEP, proteolysis by ClpP no longer depends on ATP 23 . Several related ADEP compounds are produced by Streptomyces hawaiensis 24 , and a more potent derivative, ADEP4 (Fig. 1) , showed good activity against a variety of Gram-positive bacteria 19 . ADEP4 was efficacious in a lethal systemic murine infection of Enterococcus faecalis and S. aureus and in lethal sepsis caused by Streptococcus pneumoniae in the rat 19 . Nascent polypeptides emerging from the ribosome, rather than mature folded proteins, were proposed to be primary targets of ADEP4/ClpP 23 . This would indicate that ADEP4 targets growing cells with active protein synthesis. A particular mature protein, FtsZ, has been reported to be a major target of ADEP4/ClpP 25 . FtsZ forms the cell division ring, suggesting activity of ADEP4 against growing cells as well.
Here we sought to examine the ability of ADEP4 to activate protein degradation in non-growing cells and find that in its presence, ClpP becomes a fairly nonspecific protease. Null clpP mutants are resistant to ADEP4 (ref. 19 ), but we find that they are highly susceptible to killing by a variety of antibiotics. Combining ADEP4 with rifampicin leads to eradication of persisters in growing, stationary and biofilm populations of S. aureus in vitro, and clears a deep-seated murine biofilm infection that is untreatable with conventional antibiotics. 
ADEP4 causes extensive protein degradation
Previous studies showing that ADEP targets nascent peptides and FtsZ in particular were performed with short exposure times and with rapidly growing cells, and we considered the possibility that longer incubation with ADEP may result in nonspecific degradation of proteins in nongrowing cells. A stationary phase population of S. aureus was chosen to test this, as cells are not dividing and synthesis of nascent polypeptides is strongly downregulated 26 . Stationary cells of methicillin-resistant S. aureus (MRSA) were exposed to ADEP4 for 24 h and the resulting proteome was compared with that of an untreated control (Fig. 2) .
Proteomic analysis of untreated stationary cells led to the detection of 1,712 proteins (65% of the predicted open reading frames). Treatment c, Function-enrichment analysis of proteins degraded by ADEP4. Functions overrepresented among proteins degraded by ADEP4 were annotated using Database for Annotation, Visualization and Integrated Discovery (DAVID) and the overrepresented pathways compared to the genome background are shown as columns, whereas their P-values are represented by the black dots. Bayesian moderated t-test was used to provide P-values that were further corrected by the data set size.
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with ADEP4 resulted in decreased abundance of 243 proteins (P # 0.05 and twofold decrease) ( Table 1 ). However, this is probably an underestimate. The proteome reports changes in the relative abundance of peptides produced by exogenous trypsin cleavage. A protein only cleaved once by ADEP4/ClpP, for example, would still generate several tryptically derived peptides, and not appear to show an overall decrease in protein abundance.
To address this, we examined partially tryptic peptides to uncover additional ADEP4/ClpP targets (Fig. 2b) . Partially tryptic peptides exist following trypsin treatment at certain abundance in cells due to natural degradation. However, the levels of these peptides changed markedly due to degradation induced by addition of ADEP4 (red spots). An increase of partially tryptic peptides indicates ADEP4-dependent degradation of a protein. This analysis revealed 174 additional ADEP4/ClpP targets (peptides of increased abundance; Fig. 2b ; Supplementary Table 2) , bringing their total number to 417. A decrease on the other hand indicates that a particular degradation product, present at the time of ADEP4 addition, can be further degraded by ADEP4/ClpP, but these are of less relevance to the study.
Essential ribosomal proteins were among the most strongly diminished by ADEP4/ClpP, with proteins S21, L9, S1 and ribosomal recycling factor all showing between 17-and 64-fold reduction in the ADEP4 treated sample. Elongation factor Tu, pyruvate kinase and fructose bi-phosphate aldolase were among the proteins with the largest increase in non-trypsin cleavage sites (Fig. 2b) . FtsZ was also one of the many strongly degraded proteins perhaps because of its disordered carboxy terminus 27 . Other than the ribosome, degraded proteins belonged to various functional types, including purine metabolism, glycolysis and aminoacyl-tRNA biosynthesis, among others (Fig. 2c) .
ADEP4 kills persister cells
The proteomic data indicates that ADEP4 forces the cell to self-digest, and may be effective in killing dormant cells. ADEP4 uncouples ClpP from the requirement to use ATP, which would help kill persisters with low energy levels 15 . In a control experiment, ciprofloxacin was added to an exponentially growing culture of S. aureus, which produced a typical biphasic killing pattern with surviving persisters (Fig. 3a) . Addition of rifampicin to surviving persisters had no effect on their viability, in agreement with previous observations on the multidrug tolerant nature of these cells 3, 28 . By contrast, addition of ADEP4 led to eradication of persisters to the limit of detection (Fig. 3a) . Next, we examined the ability of ADEP4 to kill stationary cells of S. aureus. Stationary phase S. aureus cells behave as persisters and are extremely difficult to kill with antibiotics 28, 29 , even over a 5-day period (Fig. 3b) . Furthermore, combinations of vancomycin, rifampicin and ciprofloxacin had limited activity against this population (Extended Data Fig. 1 ). ADEP4 showed excellent killing, decreasing the cell count of a stationary culture by 4 log 10 in two days (Fig. 3c) , but the population rebounded after day 3. Null mutants of clpP are resistant to ADEP4 (ref. 19 ) and arise with high frequency because ClpP is not essential in S. aureus. No cross-resistance to marketed antibiotics was identified for ADEP4 (ref. 19 ). Sequencing of 9 isolates of this culture showed mutations in clpP, and all of them displayed the temperature-sensitive phenotype characteristic of null clpP mutants 30 (Extended Data Fig. 2 ). To suppress resistant mutants, ADEP4 was paired with either rifampicin, linezolid or ciprofloxacin. ADEP4 with rifampicin eradicated a stationary population of S. aureus to the limit of detection (Fig. 3d) . This shows that ADEP4, unlike conventional antibiotics, has a remarkable ability to kill drug-tolerant persister cells. The rich Mueller-Hinton broth (MHB) in which these experiments were performed probably does not reflect conditions in vivo where pathogens experience nutrient limitation. We therefore tested susceptibility to killing of stationary cells in a chemically defined medium 31 . Killing in the minimal medium by ADEP4 with rifampicin was even more effective than in MHB, eradicating the population in 24 h (Fig. 3e) . Complete sterilization in these experiments was unexpected-the frequency of clpP mutants is 10
26
, and in a population of 10 9 cells, there should have 
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been 10 3 survivors. To investigate this, a clpP mutant was examined for its susceptibility to linezolid and rifampicin (Fig. 3f) . The DclpP strain had the same minimum inhibitory concentration (MIC) as the wild type, but stationary phase counts were reduced 10-to 100-fold more than the wild type by linezolid or rifampicin in stationary state. A mutation in clpP apparently diminishes the fitness of cells and makes them vulnerable to certain antibiotics. In agreement with this, a clpP mutant was reported to be avirulent in a murine skin abscess model of infection 30 . We then tested the eradicating potential of the ADEP4 and rifampicin combination against a variety of S. aureus strains. These included the laboratory strain SA113, as well as clinical isolates USA300, UAMS-1 and strain 37. USA300 is a community acquired MRSA and is the most common cause of staphylococcal skin and soft tissue infections in the United States 32 . UAMS-1 is a highly virulent clinical isolate associated with chronic osteomyelitis 33 . Strain 37 was isolated from a patient undergoing vancomycin therapy who succumbed to infection 34 . No colonies were detected in any of these strains after 72 h of incubating stationary cultures with ADEP4 and rifampicin (Fig. 4) .
ADEP4 with rifampicin eradicates biofilm
Biofilms produced by the osteomyelitis-associated strain UAMS-1 displayed a similar tolerance to antibiotics as stationary phase cultures (Fig. 5) . ADEP4 showed considerable killing following 24 h of treatment, but the population rebounded after 72 h. Again, a combination of ADEP4 with rifampicin resulted in eradication of living cells in the biofilm to the limit of detection (Fig. 5) . The replacement of antibiotics with fresh medium did not result in re-growth after 3 days of ADEP4 and rifampicin treatment, confirming the complete eradication of living cells. An elimination of a biofilm is unprecedented for such low, clinically achievable concentrations of compounds.
ADEP4 with rifampicin eradicates infection
Eradication of stationary and biofilm populations was an encouraging sign that ADEP4 could be a very useful antibiotic against untreatable chronic infections. To test this, we used a deep-seated mouse thigh infection model. In a standard thigh model, a mouse is infected with a low dose of pathogen and antibiotic therapy begins within a few hours of infection. Under these conditions, conventional antibiotics are very effective. In the deep-seated model, the mouse is made neutropenic by treatment with cyclophosphamide, a large dose of pathogen is delivered and the infection is allowed to develop for 24 h before therapy, leading to a severe, recalcitrant, deep-seated infection. This model emulates a difficult to treat human deep-seated chronic infection in immunocompromised patients. We performed histopathology of the infected thigh and detected massive aggregates of S. aureus cells with Gram staining (Fig. 6a) . Electron microscopy of cross-sections of the infected tissue revealed S. aureus growing in biofilms adhered to muscle cells (Fig. 6a) . Administration of vancomycin, rifampicin or a combination of both decreased the viable counts, but did not clear the infection (Fig. 6b) . Furthermore, no notable difference was observed between mice treated for 24 h or 48 h with vancomycin in this model, indicating the presence of a persister subpopulation surviving the antibiotic treatment (Fig. 6b) . Remarkably, an ADEP4 and rifampicin combination led to sterilization of the infected tissue to the limit of detection within 24 h (Fig. 6c) . Based on this efficacious dose and the mouse pharmacokinetics data 19 , we performed a hollow-fibre experiment and found that the combination of ADEP4 and rifampicin also resulted in complete eradication of the pathogen to the limit of detection (Extended Data Fig. 3 ).
Discussion
The rise in biofilm infections is a recent phenomenon, mainly a sideeffect of medical intervention 35 . Biofilms form readily on indwelling devices such as catheters, prostheses and heart valves. Biofilms have a complex architecture and developmental program 36, 37 and form a protective environment for persisters, shielding them from the immune system. In patients undergoing cancer chemotherapy or organ transplantation or in the elderly, the immune system is compromised, enabling deep-seated infections in soft tissues to take hold. Even disseminating infections of S. aureus are difficult to eradicate in immunocompromised patients. The dormant state of persisters and the multiplicity of the pathways leading to their formation make treatment of chronic infections unusually challenging. Our results demonstrate that persister cells in a biofilm can be killed with a protease-activating antibiotic. This study shows that persisters are not invulnerable, and helps settle an important uncertainty surrounding chronic diseases-it has been unclear whether conventional antibiotics fail owing to their ineffective killing or simply because they do not reach all pathogens at the site of infection. We had previously described high-persister (hip) mutants that are selected in the course of antibiotic treatment in patients with Candida albicans biofilms 38 or with Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis 39 . Selection for increased production of persister cells suggests that antibiotics effectively reach the pathogens. Sterilization of a deep-seated biofilm infection with ADEP4, but not with conventional antibiotics, shows directly that the problem indeed lies in pathogen tolerance. Pathogens surviving antibiotic treatment in a chronic infection are detrimental not only to a given patient, but to society as well. A large, lingering population of pathogens is 
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fertile ground for the development of resistance [40] [41] [42] . The ability to efficiently eradicate an infection will help reduce the spread of resistance.
ADEP4 is remarkable in its ability to kill dormant cells. Persisters formed by competitors would present an obvious problem for Actinomycetes, and it is perhaps not surprising that they evolved compounds capable of killing both growing and dormant cells. ADEP4 points to a general principle of killing, activation and corruption of a target (Extended Data Fig. 4) . Apart from ADEP4, other activators of ClpP 43 may be developed into therapeutics, and additional bacterial proteases such as Lon could be used as targets for killing specialized survivor cells. This general principle of killing may be applied to other organisms as well and prove effective in developing therapeutics to treat fungal infections and cancer.
METHODS SUMMARY
In all experiments, bacterial cells were cultured in 20 ml of Mueller-Hinton (MH), brain heart infusion (BHI) broth or chemically defined media 31 at 37 uC and were aerated at 225 r.p.m in 250 ml flasks. Antibiotics were applied at the following concentrations, corresponding to 103 MIC: vancomycin 10 mg ml 21 , ADEP4 5 mg ml 21 , rifampicin 0.4 mg ml
21
, linezolid 10 mg ml 21 and ciprofloxacin 3 mg ml
. MICs were the same for each strain examined. The strains used in this study were S. aureus: ATCC 33591, UAMS-1, USA300, SA113 and strain 37 (ref. 34) . Biofilm survival assays were performed in 96-well polystyrene plates in BHI broth in a static 37 uC incubator. Biofilm was allowed to develop for 24 h. Wells were gently washed with PBS and fresh medium containing antibiotics was added to each well. Biofilms were incubated for either 24 or 72 h. Biofilms were then washed and sonicated in PBS. Serial dilutions were performed and 10 ml aliquots were spotted on BHI agar. iTRAQ proteomics was performed on stationary phase ATCC 33591 treated with 103 MIC of ADEP4 for 24 h and compared to an untreated control. Mouse experiments were performed with female 6-week-old Swiss-Webster (Taconic) mice that were first rendered neutropenic by cyclophosphamide treatment (150 mg per kg and 100 mg per kg 96 h and 24 h before infection, respectively). Infection was allowed to develop for 24 h before commencement of antibiotic therapy. All antibiotics were delivered intraperitoneally. Animal experiments were carried out at Northeastern University and conformed to institutional animal care and use policies.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
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